Ambea AB/Skr AMBEA
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Ambea AB
Ambea AB is a company operating within the healthcare and social services industry, primarily offering care services in the Nordic region. The company provides elderly care, disabled care, and psychosocial support services, focusing on high-quality living and well-being for its users. Founded in 1996, Ambea is headquartered in Stockholm, Sweden, and operates through several brands, including Vardaga and Nytida, ensuring a broad service coverage across Sweden, Norway, and Denmark. The company is strategically positioned through its strong regional presence and an extensive network of facilities and professionals, enabling efficient service delivery and high standards of care.
- Ticker
- Skr AMBEA
- Sector
- Health
- Primary listing
- XSTO
- Employees
- 41,000
- Headquarters
- Solna, Sweden
- Website
- www.ambea.se
Ambea AB Metrics
BasicAdvanced
kr 15B
19.38
kr 9.54
0.67
kr 2.65
1.43%
Price and volume
Market cap
kr 15B
Beta
0.67
52-week high
kr 189.80
52-week low
kr 112.70
Average daily volume
156K
Dividend rate
kr 2.65
Financial strength
Current ratio
0.407
Quick ratio
0.363
Long term debt to equity
2.073
Total debt to equity
2.571
Dividend payout ratio (TTM)
26.94%
Interest coverage (TTM)
2.83%
Profitability
EBITDA (TTM)
1,648
Gross margin (TTM)
27.89%
Net profit margin (TTM)
4.63%
Operating margin (TTM)
8.44%
Effective tax rate (TTM)
21.38%
Revenue per employee (TTM)
kr 410,000
Management effectiveness
Return on assets (TTM)
4.23%
Return on equity (TTM)
15.50%
Valuation
Price to earnings (TTM)
19.378
Price to revenue (TTM)
0.895
Price to book
2.89
Price to tangible book (TTM)
-3.81
Price to free cash flow (TTM)
6.921
Free cash flow yield (TTM)
14.45%
Free cash flow per share (TTM)
26.716
Dividend yield (TTM)
1.43%
Forward dividend yield
1.43%
Growth
Revenue change (TTM)
13.87%
Earnings per share change (TTM)
28.00%
3-year revenue growth (CAGR)
9.45%
3-year earnings per share growth (CAGR)
38.48%
3-year dividend per share growth (CAGR)
28.46%
What the Analysts think about Ambea AB
Analyst ratings (Buy, Hold, Sell) for Ambea AB stock.
Analyst projections of the future price of Ambea AB stock.
Bulls say / Bears say
Second-quarter sales rose 7% year on year, while adjusted EBITA increased 28% and its margin improved to 9.0% from 7.6%. That points to stronger profitability as well as growth. (Inderes)
Ambea’s pipeline contains more than 2,200 new care places planned for 2026–30, with estimated revenue of about SEK 2.7 billion once fully ramped up. This gives the company a substantial route to future organic growth, although new sites take time to fill. (Investing.com)
Rolling 12-month free cash flow reached SEK 929 million, while leverage fell to 2.4 times EBITDA. That cash generation and lower debt give Ambea room to fund growth and return capital to shareholders. (Earningscalls.dev)
After the Humana combination, Ambea expects to regain its 9.5% adjusted EBITA margin target only by the end of 2028. The combined business had an 8.4% margin on the stated comparable basis, leaving execution and integration work to do. (EFN)
Vardaga expects to hand back contracts with annual turnover of SEK 199 million over the next 12 months. If replacement contracts or new sites ramp up slowly, that could weigh on sales. (Investing.com)
Management said constrained municipal budgets in Norway have changed purchasing behaviour and continue to affect adult-care occupancy. That creates a risk to demand and staffing efficiency in an important market. (Investing.com)
Data summarised monthly by Lightyear AI. Last updated on 12 Oct 2026.
Ambea AB Financial Performance
Revenues and expenses
Ambea AB Earnings Performance
Company profitability
Upcoming events
No upcoming events
Funds containing Ambea AB
Fund name | Fund size | Skr AMBEA weighting |
|---|---|---|
iShares Ageing Population$AGED | $953M | 0.13% |
iShares Ageing Population£AGES | $953M | 0.13% |
iShares Ageing Population€AGED | $903M | 0.13% |
Xtrackers MSCI Europe Small Cap£XXSC | $3.6B | 0.09% |
Xtrackers MSCI Europe Small Cap€DX2J | $3.6B | 0.09% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.